Stansberry Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$25.5M Sell
21,241
-183
-0.9% -$187K 2.33% 8
2026
Q1
$19.7M Sell
21,424
-9
-0% -$9.12K 2.03% 9
2025
Q4
$23M Buy
21,433
+5,599
+35% +$5.35M 2.33% 9
2025
Q3
$12.1M Buy
15,834
+4,282
+37% +$3.19M 1.26% 29
2025
Q2
$9.01M Buy
11,552
+28
+0.2% +$21.8K 0.98% 43
2025
Q1
$9.52M Buy
11,524
+1,429
+14% +$1.19M 1.14% 35
2024
Q4
$7.79M Buy
10,095
+3,021
+43% +$2.5M 1.01% 42
2024
Q3
$6.27M Buy
7,074
+479
+7% +$431K 0.78% 50
2024
Q2
$5.97M Buy
6,595
+1,115
+20% +$892K 0.78% 52
2024
Q1
$4.26M Buy
5,480
+685
+14% +$487K 0.58% 63
2023
Q4
$2.8M Buy
+4,795
New +$2.8M 0.46% 69

Other funds holding LLY

Stansberry Asset Management's LLY Position: Q2 2026 in Review

Stansberry Asset Management reduced its Eli Lilly (LLY) stake by 0.85% in Q2 2026, selling an estimated $187K and leaving 21,241 shares worth $25.5M. The position accounts for 2.33% of the portfolio, ranked #8.

Stansberry Asset Management first reported a position in LLY in Q4 2023 and has held it in 11 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Stansberry Asset Management held 21,241 shares of Eli Lilly worth $25.5M as of Q2 2026.
  • Stansberry Asset Management sold 183 Eli Lilly shares in Q2 2026, an estimated $187K.
  • Eli Lilly made up 2.33% of Stansberry Asset Management's portfolio in Q2 2026, its #8 holding.
  • Stansberry Asset Management first reported a position in Eli Lilly in Q4 2023 and has held it in 11 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Stansberry Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.